Last reviewed · How we verify
LAS41004
At a glance
| Generic name | LAS41004 |
|---|---|
| Also known as | fixed combinations of retinoid and steroid |
| Sponsor | Almirall, S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis (PHASE2)
- Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test (PHASE2)
- Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis (PHASE2)
- Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis (PHASE2)
- Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test (PHASE1, PHASE2)
- Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAS41004 CI brief — competitive landscape report
- LAS41004 updates RSS · CI watch RSS
- Almirall, S.A. portfolio CI